FDA SIUU Guidance in 2026 and the Decision to Publish

TL;DR

FDA's January 2025 guidance on scientific information on unapproved uses, or SIUU, presents a documentary conflict that requires reconciliation before a publication review assigns an implementation status. On October 11, 2026, its official page and PDF still display a not-for-current-implementation notice pending an Office of Management and Budget decision. Yet later primary records show relevant information-collection approvals and an FDA announcement. The unchanged notice and the later approval records both belong in that account. [1] [2] [3] [4] [5]

Three decisions matter for a life-sciences company publishing across websites, medical channels and distributor networks. First, reconcile the guidance notice with the subsequent administrative record before stating a definitive implementation conclusion. Second, classify the actual communication: product, use, audience, initiating party, source material and surrounding claims. Third, preserve a reviewable connection between the approved material and every derivative asset, including translations, summaries and social previews. The latter two are our operational approach to a distributed content operation, not additional FDA-prescribed forms.

Neither the unchanged notice nor the subsequent Paperwork Reduction Act approvals automatically restore an older guidance as a legal safe harbor or authorize a particular communication. Nor does a warning letter concerning a product without approval or clearance establish that a journal reprint about an unapproved use of an approved product is unlawful. This report examines the records available on October 11, 2026, with the guidance-specific implementation date unresolved. An individual publication decision still requires the company's regulatory and legal review.

Reconcile the guidance notice with the later approval record

The FDA landing page identifies the January 2025 SIUU document as final guidance and says it finalizes the October 2023 revised draft. It also displays the implementation limitation. The implementation investigation therefore extends beyond the page's final-guidance designation. [1]

The PDF's cover displays a placeholder OMB control number and identifies information-collection provisions in questions 2, 4 and 5 as under OMB review. Section VI says FDA will publish a Federal Register notice concerning OMB's decision before implementing the guidance. Those are the displayed statements, not proof that no subsequent decision or notice exists. [2]

The later record changes the analysis. The January 7, 2025 SIUU notice, docket FDA-2008-D-0053, identified revisions to collections 0910-0686 and 0910-0485. OIRA's record for the drug collection, ICR 202501-0910-004 under 0910-0686, shows approval without change on July 29, 2025. FDA's September 25, 2025 announcement includes the SIUU docket and lists both collections as approved, with expiration dates of July 31, 2028. The collection titles in that announcement are “Prescription Drug Advertisements and Product Communications” and “Medical Device Labeling Requirements.” The control numbers connect the records despite the different titles. [3] [4] [5]

These records establish completed PRA actions. Why the notice remains unchanged, and the separately stated SIUU implementation date, remain unresolved in these records. The responsible conclusion is to preserve both parts of the evidence and obtain a resolved basis before relying on a categorical implementation statement. “OMB has not yet acted” omits the later records; “the page is obsolete, so every in-scope communication is protected” goes beyond them.

This distinction matters because the guidance describes an enforcement policy, not a new product authorization. Its introduction says FDA does not intend to use dissemination of communications consistent with its recommendations, standing alone, as evidence of a new intended use. The same text also says that a communication outside the described characteristics does not, by that fact alone, establish that FDA intends to rely on it as evidence of a new intended use. Any reliance on that enforcement policy requires assessment of the particular communication. Discussion of this policy should retain the unresolved implementation-status qualification described above. [2]

An internal document register can capture this without trying to resolve every communications question in a single status field:

Sources: FDA landing page and guidance, January SIUU notice, OIRA drug-collection record and September approval announcement. The register format is an editorial implementation example, not an FDA-required form. [1] [2] [3] [4] [5]

For a publication queue, a useful status is “SIUU implementation basis requires reconciliation; assess this asset under applicable law and the company's reviewed communications policy.” That wording avoids recording an unverified administrative conclusion as though it decided the asset's complete legal status.

Start with the product and the claim

The intended-use regulations for devices and drugs explain why the content around a scientific article deserves attention. They describe objective intent as potentially shown through labeling claims, advertising and oral or written statements by the responsible parties or their representatives, as well as other relevant circumstances. Both also contain an important limitation on relying solely on a firm's knowledge of HCP prescribing or use for an unapproved use. The drug provision addresses approved drugs. The device provision addresses devices that are approved, cleared, granted marketing authorization or exempted from premarket notification. For those respective categories, the regulations exclude that knowledge alone as a basis for establishing the firm's intent for the unapproved new use. [6] [7]

Two operational consequences follow. A publication review needs to examine the surrounding content as well as the attached paper's peer-review status. It needs to examine what the firm is communicating through the complete asset. The lawfulness assessment likewise requires more than evidence that clinicians use a product in a particular way. The decision needs a defined claim and a defined communication context.

Consider a hypothetical device manufacturer, Company A. It has clearance for one indication and wants to circulate a paper studying another. The team's first question concerns the proposed communication, ahead of the mechanics of uploading the paper. It is whether the proposed asset accurately identifies the product's regulatory status and the use being discussed, what the study actually establishes, who will receive it, and how the firm introduces it. A cover email describing a preliminary finding, a sales slide promising an established clinical benefit, and a neutral bibliographic entry are different communications even if they link to the same paper.

The study's limitations also travel with the scientific claim. A headline about a small exploratory population must retain that population's limits, even when the commercial audience is broader. A summary of an association must preserve the distinction from a demonstrated treatment effect. Claims about a different configuration or comparator require their own support. These are evidence-to-claim distinctions, not special exemptions created by SIUU.

The final SIUU text discusses published source materials and firm-generated presentations supplied with a source publication. It emphasizes information needed for HCPs to assess scientific strengths, weaknesses and clinical utility. Those passages explain the policy's intended subject. Reliance on those recommendations requires assessing the complete slide deck and reconciling the administrative record described above. [2]

A practical review record can therefore begin with the exact proposed sentence and work outward. Preserve the sentence, the source passage and study population supporting it, the applicable product labeling, the audience and distribution method, and the review outcome. The decision may be to publish, revise, restrict distribution or decline the asset. The record should explain that decision rather than rely on the presence of a guidance citation as a substitute for reasoning.

Separate proactive dissemination from an unsolicited response

Identify who initiated the communication. Neither a “medical education” label nor routing through a medical-affairs mailbox establishes that a request was unsolicited. FDA's December 2011 document addresses responses to unsolicited requests and distinguishes requests initiated independently from requests prompted by a firm or its representatives. Its cover calls it draft guidance for comment, and its pages say it is not for implementation. Its draft status must remain explicit when the document is used in a review. [8]

The draft is still useful evidence of the agency's articulated considerations. It discusses limiting a response to the request and handling public requests without disseminating the full off-label response to an unrestricted public audience. The legal review record should retain that draft status and separately address the applicable statutory and regulatory questions. The document itself recognizes that a different response approach can still comply with the law. [8]

The practical distinction is easiest to see in examples. If a clinician independently sends a question about an unapproved use, the review file can preserve that request and the proposed response. If a campaign encourages recipients to request a particular off-label analysis, record the campaign's role in initiating the resulting inquiries. If a question arrives in a public comment thread, the public reply and any subsequent private exchange should be evaluated as separate communications rather than assumed to have the same audience.

For a content operator, three routing categories are more useful than a single “scientific” tag:

This is a proposed review-routing model. The underlying distinctions are informed by the SIUU guidance, the unsolicited-requests draft and intended-use regulations; the model is our editorial aid rather than an FDA classification system. [2] [6] [7] [8]

Keep the resulting review record proportionate to the communication decision. It is to prevent a material change in audience or initiation from disappearing during production. Turning a response approved for one clinician's question into a reusable public landing page requires review of the new audience and context.

Read the ExThera warning letter within its product context

FDA's 6 February 2026 warning letter to ExThera Medical Corporation is relevant to public communications because it discusses statements on websites and in other public media, including podcasts and distributor material. The agency alleged that the Seraph 100 device was adulterated and misbranded and challenged representations about its regulatory status and intended uses. The letter states that the device was not approved or cleared for any indication. These are FDA's findings and allegations in a warning letter, not a final judicial determination. [9]

That last product-status detail prevents a misleading comparison. The SIUU guidance concerns unapproved uses of products within its defined approved-or-cleared scope. Seraph 100's lack of approval or clearance, as described in the letter, differs from Company A's clearance for another indication. The warning letter's relevance to a particular in-scope SIUU communication requires separate assessment. Nor can one letter establish the prevalence of a particular industry's practice. [2] [9]

The narrower lesson is useful enough. A company's public regulatory-status statements and surrounding benefit claims deserve the same controlled review as the main product page. A distributor's page, an interview excerpt or a video description may contain a materially different claim from the approved master copy. Whether a specific third-party statement is attributable to the firm depends on the facts; the content inventory should make those relationships visible rather than assume all external statements are either irrelevant or automatically the firm's own.

For Company A, an audit would therefore ask which distributor assets the company supplied, approved, hosts or can correct; which claim each asset makes; and whether it remains consistent with the product's actual status and reviewed evidence. Finding an incorrect claim warrants a documented corrective decision. The asset-level assessment should determine which resources need correction, withdrawal or continued use.

Keep the review decision attached to derivatives

A modern publication is rarely one file. A long-form article becomes a page title, search description, social card, translated page, downloadable handout and sometimes a distributor summary. Meaning can change across versions even when each sentence is free of typographical errors. A shortened version can remove the condition that made the original statement supportable.

A proposed control for a distributed content operation is a claim-and-asset register. Unlike a general document inventory, it connects a substantive claim to the approved wording and all known derivatives. The register need not require a new software platform. Its useful fields are the claim, the evidence and labeling version, any audience or channel limitation, the approved qualification, the review decision and the derivative asset locations.

For example, suppose the reviewed sentence says that a study evaluated an investigational use in a defined population and did not establish a benefit in another population. The summary must retain the population and benefit limitations. The translation should preserve the uncertainty and the population boundary. The social card must preserve the distinction between a study question and a product promise. These acceptance checks follow from the meaning of the claim, not from an invented requirement that every channel use identical text.

The production team can test four common transitions before release:

This workflow should be proportionate. A correction to punctuation need not be treated like a new therapeutic claim. A change in indication, audience, evidence interpretation or regulatory status is different: it can alter the basis on which the asset was approved. The organization should define those material-change triggers in its own procedure and assign reviewers with the relevant expertise.

A successful content operation also preserves negative decisions. If reviewers reject a headline because it overstates the study, keep that reason next to the approved alternative. Otherwise, the same stronger headline may reappear in another language or channel after a team member treats the original objection as a stylistic preference.

What to change in the next publication cycle

The immediate priority is to identify decisions that rest on an incomplete status assumption in either direction. Search the review register for approvals based solely on the word “final,” and for restrictions based solely on an assertion that OMB has not acted. A reference to the guidance can remain appropriate when its use and status are accurately described. The issue is a decision rationale that omits material administrative evidence.

For each affected decision, retain the original record and add the reassessment. Preserve the review history and assess the relevance of older guidance before replacing a citation. FDA's landing page describes the sequence from the 2009 final through the 2014 and 2023 drafts to the 2025 final; establishing the current legal basis for a specific communication requires more than that lineage. [1]

Next, prioritize assets by the consequence of a claim error: incorrect authorization statements, expanded indications, unsupported safety or effectiveness claims, and versions with changed audiences. This prioritization is an editorial recommendation, not a claim that FDA has prescribed that sequence. The appropriate disposition depends on each asset's content and context.

Finally, assign an owner to reconcile the FDA landing page and PDF with the January notice, the OIRA decision and the September announcement, and to seek further authoritative clarification where needed. Treat the approval announcement as an existing part of the record. Record the basis for any resolved implementation conclusion and which procedure or asset decisions need reconsideration. Each study summary and communication still needs its own verification and approval assessment. [1] [2] [3] [4] [5]

For leadership, keep publishing decisions grounded in the product's actual status, the evidence and the complete communication. Read the unchanged web notice and subsequent administrative approvals together, retaining the uncertainty that remains. For the team operating the global website and content pipeline, the deliverable is a defensible decision that survives translation and redistribution—not merely a completed compliance checkbox.

For help operating reviewed content across websites, languages and distribution channels, explore VayoMed's Done-for-You Growth Engine. Operational support remains subject to the client's medical, legal and regulatory approval; the client retains responsibility for that review and any required regulatory authorization.

Sources

1. U.S. Food and Drug Administration. Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products. January 2025 guidance landing page; status checked 11 October 2026.

2. U.S. Food and Drug Administration. SIUU Questions and Answers, final guidance PDF. January 2025. Cover; sections I, II, IV and VI. Final guidance marked not for current implementation.

3. FDA. SIUU guidance availability and information-collection submission notice. January 7, 2025, 90 FR 1146–1150, docket FDA-2008-D-0053; identifies revisions to OMB collections 0910-0686 and 0910-0485.

4. Office of Information and Regulatory Affairs. ICR 202501-0910-004, Prescription Drug Advertisements and Product Communications. OMB control 0910-0686; approved without change July 29, 2025; checked October 11, 2026.

5. FDA. Agency Information Collection Activities; Announcement of OMB Approvals. September 25, 2025, 90 FR 46225. Heading includes docket FDA-2008-D-0053; Table 1 lists 0910-0686 and 0910-0485 with July 31, 2028 expiration dates.

6. Electronic Code of Federal Regulations. 21 CFR 801.4, Meaning of intended uses. Device intended-use regulation; consulted 11 October 2026.

7. Electronic Code of Federal Regulations. 21 CFR 201.128, Meaning of intended uses. Drug intended-use regulation; consulted 11 October 2026.

8. U.S. Food and Drug Administration. Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices. December 2011 draft guidance; cover; section II, printed page 3; sections III–VI, printed pages 4–12. Draft and not-for-implementation status must be retained when citing its recommendations.

9. U.S. Food and Drug Administration. ExThera Medical Corporation, warning letter 715068. 6 February 2026. Agency allegations concerning Seraph 100 regulatory status and public communications.